Startups
Canary Cure Therapeutics is developing metabolic medicines through HYPER-15⢠Active Fusion delivery and Canary Atlas AI.
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2024 | Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management | CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing NEW YORK, NY, UNITED STATES, November 18, 2024 /EINPresswire.com/ -- Canary Cure, a biotechnology company focused on ... |
| Aug 19, 2024 | Canary Cure Advances Novel siRNA Therapeutic Targeting Obesity into In Vivo Trials | First-in-Class Gene-Targeted Approach to Promote Fat-Burning, Preserve Lean Body Mass, and Enhance Metabolic Health by Harnessing the Endocannabinoid System VANCOUVER, ONTARIO, CANADA, August 19, 2024 /EINPresswire.com/ -- Canary Cure, a bi... |
Reviews 0
FAQ about Canary Cure Therapeutics
What has the press written about Canary Cure Therapeutics?
Parsers VC has collected 3 articles mentioning Canary Cure Therapeutics, among them “Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management” (Nov 18, 2024) and “Canary Cure Advances Novel siRNA Therapeutic Targeting Obesity into In Vivo Trials” (Aug 19, 2024).
Is Canary Cure Therapeutics still active?
Yes, Canary Cure Therapeutics is active; its latest activity on Parsers VC dates from Oct 14, 2025.